Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.

  1. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 103

    Autism spectrum disorderASDis a continuum of neurodevelopmental characteristics that includes deficits in communication and social interactionas well as restrictiverepetitive interests and behaviorsASD is an increasing public health concernwith aboutinAmerican children diagnosed with ASD inafold increase in prevalence over the pastyearsThe effect of ASD on both society and the economy is a large b ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. In Vivo Studies of a Novel HDAC Inhibitor for Treating Hemoglobin Disorders

    SBC: Cetya Therapeutics, Inc.            Topic: NHLBI

    PROJECT SUMMARY Thehemoglobinopathies are prevalent genetic blood diseases with few treatment optionsIt is estimate thatof the worldandapos s population carries an abnormal hemoglobin gene withinfants born annually with a severe life threatening hemoglobinopathyDrug mediated induction of normalbut developmentally silencedfetal hemoglobinHbFexpression reduces anemia and ameliorates clinical severit ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Home-Based and Low-Cost ECG Device for periodic evaluation of the presence of atrial fibrillation

    SBC: Global Instrumentation, LLC            Topic: 600

    Abstract Atrial fibrillationAFprevalence is estimated toof the general population in the United StatesA shockingtoaccording to studiesof patients with AF are unaware of their diagnosissilent AFMost AF patients will suffer from congestive heart failure or and develop thromboembolic events leading to a dramatic reduction of patientsquality of lifeand a significant consumption of health care resource ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Oxidation-resistant Anti-protease Therapy

    SBC: LEXEO Therapeutics LLC            Topic: NHLBI

    AbstractLEXEO TherapeuticsLLCis an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stressLEXthest LEXEO productis ast in classnext generation gene therapy treatment for alphaantitrypsinAATdeficiencyan autosomal recessive hereditary disorder associated with low serum levels of AATAATSERPINAakDa serine antiprotease produced by th ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    Project Summary As part of the FDA approval process for novel therapeutic drugssafety screening demonstrating that the candidate drug does not have deleterious effects on the human cardiac action potential is requiredHealthy human heart cells are not available for such preclinical drug testingThere is currently no consensus on the best experimental approach to provide the most efficienteconomicala ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIAID

    TypeDiabetesT Daffects an ever growing populationWhile this disease typically has been associated with juvenilesthe disease in adult populations is rapidly increasingThe defining clinical component is insulin losswhich occurs because of sustained inflammation in the isletsAt present there is no means to prevent or reverse insulin lossA major inflammatory pathway in T D that contributes to insulin ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Automated Assessment of Leptomeningeal Collaterals on CT Angiograms

    SBC: Kitware, Inc.            Topic: 108

    AbstractThe primary goal of this study is to develop an automated scoring system of leptomeningeal collaterals based on CT angiographyCTAas a quantitative assessment of acute ischemic strokeLeptomeningeal collaterals provide an alternate path of blood flow in the setting of a proximal vessel occlusionThe presence and effectiveness of leptomeningeal collateralsi ecollateral statusvaries significant ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a Clinical Screening Platform for Type 1 Diabetes

    SBC: Op-T-Mune, Inc            Topic: NIDDK

    AbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Mobile Augmented Screening Tool to Increase Adolescent HIV Testing and Linkage to Care

    SBC: Digital Health Empowerment, Inc            Topic: NICHD

    ABSTRACTAdolescents face increased HIV riskinfrequent testinginconsistent linkage to careand a lack of prevention related knowledgeWe propose to address this by completing and evaluating the Mobile Augmented ScreeningMAStool to increase youth HIV testing via a tablet based intervention in clinical settingsand then use text messages to facilitate linkage to care for those who test positiveand deliv ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity

    SBC: Colorado Research Partners LLC            Topic: 300

    Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government